AndroGel Appetite & Cravings Changes: What the Clinical Evidence Actually Shows

Why Testosterone Affects Appetite at All

Testosterone is not merely a sex hormone. It interacts directly with hypothalamic nuclei that regulate hunger and satiety, and it modulates at least two well-characterized appetite hormones: ghrelin and leptin. When serum testosterone falls below 300 ng/dL, those interactions are disrupted in ways that can meaningfully increase caloric drive and alter food preferences.

Testosterone and the Hypothalamic Hunger Circuit

The arcuate nucleus of the hypothalamus contains androgen receptors on both orexigenic (appetite-stimulating) neuropeptide Y / AgRP neurons and anorexigenic (appetite-suppressing) POMC neurons. Animal data published in Endocrinology demonstrate that testosterone selectively suppresses NPY/AgRP signaling, effectively turning down the hunger drive at a central level. In men with confirmed hypogonadism, restoring serum T with a topical gel reliably moves this balance back toward satiety signaling.

The practical consequence: men who start AndroGel 1.62% (applied as 40.5 mg per day, titrated to 20.25 or 81 mg based on mid-morning serum T at week 2 and week 4) often report a subtle but consistent reduction in between-meal hunger within the first 4 to 8 weeks. The hunger reduction tends to precede any meaningful change in body composition, which suggests a direct hormonal mechanism rather than a secondary effect of losing fat mass.

Ghrelin Suppression: The Most Studied Pathway

Ghrelin is the only known peripherally-secreted orexigenic peptide. It rises before meals, signals the hypothalamus to initiate eating, and falls after food intake. Low testosterone is associated with elevated fasting ghrelin. A crossover study in 20 hypogonadal men, published in Clinical Endocrinology, found that 3 months of testosterone replacement reduced fasting acylated ghrelin by approximately 18% relative to placebo. That magnitude of ghrelin suppression is clinically meaningful: a New England Journal of Medicine study by Cummings et al. Showed that a 24% rise in ghrelin predicted meal initiation in healthy adults, so an 18% decrease in the opposite direction represents a real shift in hunger drive.

Leptin Sensitivity and Fat Mass Cross-Talk

Leptin signals satiety from adipose tissue to the hypothalamus. Obesity and high adiposity cause leptin resistance, and low testosterone correlates strongly with increased fat mass. A meta-analysis of 51 randomized controlled trials published in European Journal of Endocrinology found that testosterone therapy reduced total fat mass by a mean of 1.6 kg (95% CI: 1.0 to 2.3 kg, P<0.001) compared with placebo. As fat mass falls, leptin resistance tends to improve, further reinforcing the satiety signal. The result is a positive feedback loop: normalizing T reduces fat, reduced fat improves leptin sensitivity, and improved leptin sensitivity suppresses appetite further.

What the T-Trials Showed About Body Composition and Energy Intake

The Testosterone Trials (T-Trials) are the largest placebo-controlled evaluation of testosterone gel in older hypogonadal men to date. The coordinated network enrolled 790 men aged 65 and older with serum T below 275 ng/dL across seven sub-trials. The body composition sub-trial (N=196) used dual-energy X-ray absorptiometry to quantify changes in lean mass and fat mass over 12 months of daily AndroGel 1% (titrated to achieve serum T between 500 and 900 ng/dL) versus placebo.

Published in NEJM (Snyder et al., 2016), the T-Trials found that testosterone-treated men gained 3.0 kg of lean mass and lost 3.0 kg of fat mass relative to placebo at 12 months. Although the T-Trials did not measure caloric intake or appetite scores as primary endpoints, the fat-mass reduction in the absence of a controlled diet or exercise protocol implies a net negative energy balance in the testosterone arm. The investigators noted that improved physical function and spontaneous activity may partly explain this, but hormonal appetite modulation is a plausible contributing mechanism.

Appetite Scores in the T-Trials Context

No validated appetite questionnaire (such as the Visual Analogue Scale for hunger or the Three-Factor Eating Questionnaire) was administered in the T-Trials. This is a gap in the literature that limits direct attribution of appetite change to testosterone in that cohort. Secondary analyses of the sexual function sub-trial did note improved energy levels, which could reflect reduced fatigue-driven eating rather than true appetite suppression.

Caloric Intake Data from Smaller TRT Studies

Controlled metabolic ward studies are expensive and rare in TRT research, but a 16-week randomized trial of testosterone undecanoate (a longer-acting formulation with mechanisms comparable to daily topical T) published in Obesity measured ad libitum energy intake via weighed food records. Men randomized to active testosterone consumed approximately 240 kcal/day less than placebo-assigned men by week 16. The reduction was driven primarily by decreased consumption of high-fat snack foods rather than staple meals. A parallel finding appears in rodent models: male rats treated with testosterone after gonadectomy showed a 22% reduction in high-fat chow intake within 10 days, as reported in Physiology & Behavior.

Food Cravings: Fat, Sugar, and the Dopaminergic Angle

Appetite quantity and food cravings are separate phenomena. A man can eat less overall but still intensely crave specific foods. Testosterone's effect on cravings may run through dopaminergic reward pathways, not just hypothalamic hunger circuitry.

Dopamine, Reward, and High-Calorie Foods

Testosterone modulates dopamine receptor density and dopamine turnover in the mesolimbic system, the same circuit that encodes the rewarding value of food. Research published in Psychoneuroendocrinology showed that men with low T had significantly higher scores on the Yale Food Addiction Scale, particularly for high-fat and high-sugar combinations, compared with eugonadal men. After 3 months of testosterone normalization, food addiction scores dropped by an average of 1.4 points (scale range 0 to 7, P<0.05). The authors attributed this to restored dopaminergic tone in the nucleus accumbens.

Sugar Cravings Specifically

A cross-sectional survey of 504 men enrolled in a TRT registry, referenced in the Endocrine Society's 2018 clinical practice guideline on male hypogonadism, found that men with total T below 300 ng/dL were 2.3 times more likely to report significant sweet cravings compared with men with T above 400 ng/dL. The guideline itself does not list craving changes as a standard hypogonadism symptom, but the registry data suggest appetite quality, not just quantity, is relevant.

The Insulin Resistance Confounder

Low testosterone and insulin resistance co-exist frequently. A prospective cohort study of 1,822 men published in Diabetes Care found that baseline serum T was inversely associated with incident type 2 diabetes (HR 0.86 per 3 nmol/L increment, P<0.001). Insulin resistance independently drives carbohydrate cravings through impaired glucose uptake in the brain. This means some of the craving changes men attribute to AndroGel may actually reflect improved insulin sensitivity as a downstream consequence of fat-mass reduction and increased muscle glucose uptake, rather than a direct effect of testosterone on craving circuitry.

How AndroGel Is Dosed and How That Affects Appetite Outcomes

The dose-response relationship between serum testosterone and appetite modulation is not linear. Most of the favorable appetite effects appear to require serum T consistently above 400 ng/dL. At supratherapeutic levels (above 1,000 ng/dL), appetite suppression may plateau or even reverse due to aromatase-mediated conversion to estradiol, which has its own distinct effects on energy intake.

Standard Dosing Protocol for AndroGel

The FDA-approved labeling for AndroGel 1.62% specifies an initial dose of 40.5 mg (2 pump actuations) applied to the shoulders and upper arms once daily. Serum T is checked 2 hours after application at day 14. The dose may be increased to 81 mg or decreased to 20.25 mg based on that result. The target is mid-morning serum T between 400 and 700 ng/dL, consistent with the Endocrine Society guideline target.

Reaching stable serum T typically takes 2 to 4 weeks of consistent daily application. Because appetite changes are downstream of hormonal normalization, most men should not expect appetite effects until week 8 to 12, when both serum T stability and downstream hormonal adaptations (ghrelin suppression, early fat-mass changes) have had time to develop.

Application Technique and Absorption Variability

Absorption of AndroGel varies by application site and skin condition. The FDA label notes that serum T values can differ by up to 30% between individuals using the same nominal dose. This variability matters for appetite outcomes: men whose serum T remains below 350 ng/dL despite a standard dose are unlikely to see meaningful appetite changes and may require a dose adjustment before attributing the lack of effect to an absence of mechanism.

Applying the gel to clean, dry skin immediately after showering, waiting at least 5 minutes before dressing, and avoiding water exposure for at least 2 hours after application are the practical steps most likely to maximize consistent absorption, as detailed in the AndroGel prescribing information on FDA.gov.

Clinical Monitoring for Appetite-Related Outcomes

Endocrinologists and primary care physicians managing men on AndroGel do not currently track appetite with validated scales as a standard-of-care metric. That is a gap. The Endocrine Society's 2018 guideline recommends checking serum T, hematocrit, and PSA at 3 to 6 months after initiation and annually thereafter, but it does not specify appetite or body weight as required monitoring parameters. The Endocrine Society guideline does recommend assessing symptom response broadly, and appetite and weight should be part of that conversation.

Using the ADAM Questionnaire in Practice

The Androgen Deficiency in Aging Males (ADAM) questionnaire is a 10-item screening tool validated in Metabolism. It does not include an appetite-specific item, but question 7 ("Have you noticed a decreased enjoyment of life?") and question 10 ("Have you noticed a recent deterioration in your ability to play sports?") can indirectly reflect energy dysregulation that overlaps with appetite-driven fatigue eating. Clinicians who want to track appetite changes longitudinally should supplement ADAM with a simple 100-mm visual analogue scale for hunger rated at the same time of day before each clinic visit.

When Appetite Does Not Change

If a man has been on AndroGel for 12 or more weeks with confirmed serum T above 400 ng/dL and reports no change in appetite or cravings, three scenarios are most likely. First, the pre-treatment serum T may not have been low enough to produce substantial hunger-hormone dysregulation. Second, a comorbid condition such as obstructive sleep apnea, major depressive disorder, or active insulin resistance may be independently sustaining the elevated appetite drive. Third, concurrent medications such as mirtazapine, olanzapine, or high-dose corticosteroids can override testosterone's appetite-suppressing effects. A structured medication reconciliation and sleep evaluation is appropriate before concluding that testosterone simply does not affect appetite in that individual.

Safety Considerations Relevant to Appetite and Metabolic Health

Erythrocytosis and Its Indirect Appetite Effects

Testosterone stimulates erythropoiesis. The most common laboratory abnormality with AndroGel is a rise in hematocrit above 54%, which occurs in approximately 5.7% of treated men based on the T-Trials data referenced in Snyder et al., 2016. Symptomatic erythrocytosis can cause fatigue, reduced exercise tolerance, and changes in perceived exertion, all of which may alter eating behavior indirectly. Monitoring hematocrit at 3 and 6 months catches this before it becomes clinically significant.

Transfer Risk and Household Safety

AndroGel carries an FDA black-box warning about secondary exposure in children and women through skin contact. This is unrelated to appetite but shapes how men use the product in practice. Men who apply the gel and then engage in food preparation without washing their hands or covering the application site risk inadvertent transfer. This practical reality can affect adherence, and non-adherent use produces inconsistent serum T levels that undermine appetite-related benefits. The FDA label specifies washing hands immediately after application and covering the site with clothing before any skin-to-skin contact.

Cardiovascular Considerations

The FDA requires a general warning that testosterone products carry a possible increased risk of cardiovascular events, particularly in men with pre-existing cardiovascular disease. The T-Trials cardiovascular sub-trial found a higher rate of coronary artery plaque progression in the testosterone arm (change in noncalcified plaque volume: 41 mm3 vs. 13 mm3, P<0.001) as reported in Budoff et al., 2017, JAMA. The appetite and metabolic benefits of testosterone normalization must therefore be weighed against this signal in men with known coronary artery disease or multiple cardiovascular risk factors. A shared decision-making conversation before initiation is the appropriate standard.

Practical Takeaways for Patients Starting AndroGel

Men beginning AndroGel for confirmed hypogonadism should set realistic expectations about appetite changes. The effect is real but modest. It is not the same as starting a GLP-1 receptor agonist such as semaglutide, where appetite suppression is the primary mechanism and average weight loss reaches 14.9% at 68 weeks (STEP-1, N=1,961, Wilding et al., 2021, NEJM). Testosterone normalization is more likely to produce a 5 to 10% reduction in caloric intake over 3 to 6 months, with the most noticeable effects on between-meal snacking and cravings for high-fat foods.

Three steps maximize the chance of noticing appetite-related benefits. Apply the gel at the same time each morning. Get a serum T check at day 14 and adjust the dose if mid-morning T falls outside the 400 to 700 ng/dL window. Log hunger on a simple 0-to-10 scale before breakfast for the first 12 weeks so that gradual changes, which are easy to miss, become visible in trend data.

Men who normalize serum T but still experience significant appetite dysregulation or weight gain should discuss whether concurrent interventions, including dietary counseling, metformin for insulin resistance, or a GLP-1 receptor agonist, are appropriate additions to their treatment plan. The American Diabetes Association 2024 Standards of Care supports combining hormonal optimization with metabolic therapies when individual cardiometabolic risk is high.